Merck & Co. Inc. (MRK) Reports Solid Q3 with Strong Drug Sales and Pipeline Progress

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc. (NYSE:MRK) posted third-quarter 2025 sales of $17.3 billion, up 4% from last year.

KEYTRUDA led the way with $8.1 billion in sales, rising 10%. WINREVAIR saw a sharp jump to $360 million, while CAPVAXIVE brought in $244 million. GARDASIL sales dropped 24% to $1.7 billion, and Animal Health grew 9% to $1.6 billion.

Earnings per share were $2.32 (GAAP) and $2.58 (non-GAAP), both including a $0.10 charge related to a tech transfer deal. Merck also received FDA approval for a new KEYTRUDA injection, shared promising cancer trial data, and completed its acquisition of Verona Pharma. The company now expects full-year sales between $64.5–$65 billion and raised its non-GAAP EPS forecast to $8.93–$8.98.

Merck & Co. Inc. (NYSE:MRK) is a global healthcare company that uses scientific innovation to develop and provide health solutions, including prescription medicines, vaccines, biologic therapies, and animal health products. Its primary focus is on creating treatments for various diseases, with specific efforts in oncology, vaccines, and infectious diseases.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 8 Long-Term Biotechnology Stocks to Buy and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.